App-Quantinova.ai

The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A meta-analysis.

Michael Luke Marinovich - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Skeletal muscle area and density as predictors of chemotherapy toxicity and outcomes in metastatic breast cancer.

Shlomit Strulov Shachar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Effect of chemotherapy on survival in T1c T2N0M0 medullary breast cancer: 3,976 cases from the National Cancer Data Base.

Alina M. Mateo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.

Rachel A. Freedman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Lymphovascular invasion and survival in breast cancer after neoadjuvant chemotherapy.

Ying Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Adriamycin injection

Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans.

Bryan P. Schneider - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Paclitaxel

Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17).

Naoto Kondo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Eribulin

Effect of miRNA-205 on VEGFA and FGF2 and on resistance to chemotherapeutics in breast cancer.

Yunhui Hu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Doxorubicin

Obesity as an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.

Fatih Karatas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The effect of recombinant tumor necrosis factor-thymosin-alpha1 on angiogenesis in the tumor and the effectiveness of neoadjuvant chemotherapy in locally advanced breast cancer.

Liubov Yu Vladimirova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Thymalfasin

A model for trial level prediction of long term outcome based on pathological complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC).

Valentina Nekljudova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6).

Gabriel Rinnerthaler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Bendamustine

Association between distinct intratumoral and stromal tumor infiltrating immune cells and pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).

Lucia Gonzalez-Cortijo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Addition of carboplatin to standard chemotherapy in the adjuvant treatment of unselected triple negative breast cancers (TNBC).

Marcus Vetter - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Carboplatin

The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxelHealth-related quality of life during ongoing therapy.

Yvonne Brandberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Combined effect of obesity and comorbidity on toxicity of adjuvant chemotherapy for breast cancer (BC).

Ana Fernandez Sanchez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

taxane

Predictive value of topoisomerase 1 by immunohistochemistry (TOP1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy.

Nicholas J. Robert - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fluorouracil

Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients.

Rachel Ann Sanford - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Cardiovascular disease incidence and mortality in breast cancer survivors compared to the general population: Systematic review and meta-analysis.

Marina Michelle Reeves - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The changing utilization of neoadjuvant chemotherapy among different racial groups and its effect on mastectomy rates.

Tiffany Pinchinat - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Filters

14023 Abstracts